SLS Logo on CK Group website

Initial results of Salford Lung Study released

Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’  

 

 

Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice

The highly anticipated results from the Salford Lund Study were announced by GSK on 24th May 2016 (http://www.gsk.com/en-gb/media/press-releases/2016/salford-lung-study-results-show-copd-patients-treated-with-relvar-ellipta-achieve-superior-reduction-in-exacerbations-compared-with-usual-care/). Continue reading

Posted in Key MilestonesTagged in , , , , , , , , , , ,